Overview
Anxiety disorders are the most prevalent mental health conditions globally, affecting ~280 million people (~4.8% of the world population). They encompass generalized anxiety disorder (GAD), social anxiety, panic disorder, and phobias. In the WikiBiome context, anxiety frequently appears as a comorbidity across conditions with documented microbiome dysbiosis — suggesting shared pathophysiology through the gut brain axis.
The gut-brain axis connects intestinal microbiome composition to anxiety through three primary routes: the vagus nerve (direct neural signaling), neuroactive metabolites (serotonin, kynurenine, GABA, SCFAs), and immune-inflammatory pathways (cytokines, tlr4 activation).
Microbiome Associations
Gut-Brain Axis Mechanisms
- serotonin: ~90-95% produced in the gut by enterochromaffin cells; microbially stimulated. Tryptophan diversion from serotonin to kynurenine under inflammation reduces serotonin availability.
- GABA: Produced by Lactobacillus and Bifidobacterium species; GABAergic deficits are a core anxiety mechanism.
- short chain fatty acids: butyrate modulates HPA axis reactivity and neuroinflammation; SCFA producer depletion is associated with anxiety.
- Vagal signaling: Gut-to-brain signaling via vagal afferents; probiotics' anxiolytic effects are abolished by vagotomy in animal models.
SSRI-Microbiome Bidirectionality
Selective serotonin reuptake inhibitors (SSRIs) affect gut microbiome composition, and baseline microbiome may predict treatment response — a pharmacomicrobiomics interaction [1].
Anxiety as Comorbidity
Anxiety appears as a significant comorbidity across multiple WikiBiome disease entities, suggesting shared microbiome-mediated pathophysiology:
| Condition | Anxiety Prevalence | Shared Mechanism |
|---|---|---|
| endometriosis | Elevated | Inflammatory cytokines; estrogen-serotonin interactions |
| crohns disease | 30-40% | Gut inflammation → vagal signaling → HPA axis |
| graves disease | Common | Thyroid hormone effects on neurotransmission; autoimmune inflammation |
| parkinsons disease | 25-40% | Dopaminergic dysfunction; gut-brain axis disruption |
| multiple sclerosis | 22-54% | Neuroinflammation; kynurenine pathway activation |
| fibromyalgia | 20-60% | Shared tryptophan/serotonin metabolism alteration with IBS |
| ibs | 30-50% | Visceral hypersensitivity; serotonin dysregulation |
| depression | >50% comorbid | Shared HPA axis, tryptophan, and inflammatory pathways |
Open Questions
- Which specific taxa are causally anxiogenic vs. anxiolytic? Few MR studies address anxiety specifically.
- Does metal-driven dysbiosis (via iron sulfur clusters damage to SCFA producers) contribute to anxiety through SCFA depletion?
- Can microbiome-targeted interventions (probiotics, FMT, dietary fiber) reduce anxiety in conditions where it is comorbid?
Cross-References
- depression — Primary comorbidity; shared mechanisms
- gut brain axis — Primary pathophysiological pathway
- serotonin — Key neurotransmitter linking microbiome to anxiety
- kynurenine — Tryptophan diversion under inflammation
- tryptophan metabolism — Parent metabolic pathway
- pharmacomicrobiomics — SSRI-microbiome interactions
- probiotics — Anxiolytic potential ("psychobiotics")
- synbiotics — GI and anxiety improvements in ASD (Mitchell 2024)